UNSPSC 51372201: Dextromoramide

This classification denotes an opioid receptor agonist with the molecular formula C25H32N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9S4S6CIY83, chemically known as pyrrolidine, 1-(3-methyl-4-(4-morpholinyl)-1-oxo-2,2-diphenylbutyl)-, (s)- but generally known as dextromoramide, which bears US NIH Compound Identifier 9648. European Medicines Agency schedules Dextromoramide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07052MIG.

UNSPSC 51372201 Dextromoramide is a Commodity code that encompasses pharmaceutical products, including opioid-based medications and controlled substances used in clinical, emergency-response, and public-health settings. State and local governments procure these materials primarily through health departments, public-health agencies, county health systems, and multistate cooperative purchasing alliances. The scope extends beyond the single drug name to include bundled pharmaceutical procurement where dextromoramide and related products may be packaged with complementary items—such as naloxone and drug deactivation systems—as part of community health, overdose-response, or substance-use initiatives. Issuing bodies include county health departments, state HHS commissions, and cooperative purchasing entities serving multiple jurisdictions and government employee health plans.

Recent activity shows concentrated procurement in Florida and Minnesota, with exploratory interest from Texas. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, with a response deadline of July 26, 2023. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products with a response deadline of March 26, 2026, requiring vendors to work through three authorized wholesalers and targeting availability by July 1, 2026. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to explore direct-to-manufacturer prescription programs and vendor capabilities for establishing pharmacy benefit arrangements outside traditional PBM and wholesaler channels. None of these opportunities explicitly targets dextromoramide by name; the code's recent activity reflects broader pharmaceutical and health-supply procurement where controlled substances may appear as line items within larger health-initiative purchases.